(P-2015) Evaluating the use of Monoclonal Antibodies - Sotrovimab, Casirivimab/Imedvimab (REGEN-COV) and Tixagevimab/Cilgavimab (EVUSHELD) for COVID-19 Treatment in Singapore

Saturday, October 19, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

Annabel Chua, BSc Pharmacy (she/her/hers)

Senior Pharmacist
Tan Tock Seng Hospital, National Centre for Infectious Diseases
Singapore, Singapore

PN

Puay Hoon Eve Nah, Bachelor of Information Technology

National Public Health & Epidemiology Unit (NPHEU), National Centre for Infectious Diseases
Singapore, Singapore
GH

Grace Hoo, MSc (ID), BCIDP

Tan Tock Seng Hospital, National Centre for Infectious Diseases
Singapore, Singapore
YH

Ying Hao, PhD

- National Public Health & Epidemiology Unit (NPHEU), National Centre for Infectious Diseases
Singapore, Singapore
JT

Jun Xin Tay, BSc Pharmacy

Tan Tock Seng Hospital, National Centre for Infectious Diseases
Singapore, Singapore
BY

Barnaby Edward Young, MB BChir, PhD

National Centre for Infectious Diseases, Tan Tock Seng Hospital, - National Centre for Infectious Diseases and Tan Tock Seng Hospital, Lee Kong Chian School of Medicine
Singapore, Singapore
MT

Matthias Paul Toh, - MBBS, MMED (Public Health), FAMS, Dip (Family Med), NUS, Dip (OM)

National Public Health & Epidemiology Unit (NPHEU), National Centre for Infectious Diseases, Saw Swee Hock School of Public Health, National University of Singapore
Singapore, Singapore
MC

Mark Chen, MBBS MPH PhD

National Public Health & Epidemiology Unit (NPHEU), National Centre for Infectious Diseases
Singapore, Singapore
Shawn Vasoo, MBBS, MRCP, D(ABP), D(ABIM) (Inf Dis), FRCPath

Clinical Director
National Centre for Infectious Diseases and Tan Tock Seng Hospital, Dept of Infectious Diseases
Singapore, Singapore